These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12538634)

  • 21. Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1.
    Nakamuta M; Chang BH; Zsigmond E; Kobayashi K; Lei H; Ishida BY; Oka K; Li E; Chan L
    J Biol Chem; 1996 Oct; 271(42):25981-8. PubMed ID: 8824235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of protein complexes assembled on apolipoprotein B mRNA for mooring sequence-dependent RNA editing.
    Smith HC
    Methods; 1998 May; 15(1):27-39. PubMed ID: 9614650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors.
    Sowden MP; Ballatori N; Jensen KL; Reed LH; Smith HC
    J Cell Sci; 2002 Mar; 115(Pt 5):1027-39. PubMed ID: 11870221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif.
    Yamanaka S; Poksay KS; Driscoll DM; Innerarity TL
    J Biol Chem; 1996 May; 271(19):11506-10. PubMed ID: 8626710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48.
    Hirano K; Young SG; Farese RV; Ng J; Sande E; Warburton C; Powell-Braxton LM; Davidson NO
    J Biol Chem; 1996 Apr; 271(17):9887-90. PubMed ID: 8626621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity.
    Blanc V; Henderson JO; Kennedy S; Davidson NO
    J Biol Chem; 2001 Dec; 276(49):46386-93. PubMed ID: 11571303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The hypothyroid (hyt/hyt) mouse: a model system for studying the effects of thyroid hormone on developmental changes in gene expression.
    Green RP; Birkenmeier EH; Beamer WG; Maltais LJ; Gordon JI
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5592-6. PubMed ID: 3399505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity.
    MacGinnitie AJ; Anant S; Davidson NO
    J Biol Chem; 1995 Jun; 270(24):14768-75. PubMed ID: 7782343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition.
    Elam MB; von Wronski MA; Cagen L; Thorngate F; Kumar P; Heimberg M; Wilcox HG
    Lipids; 1999 Aug; 34(8):809-16. PubMed ID: 10529091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypermutation induced by APOBEC-1 overexpression can be eliminated.
    Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Csako G; Patterson AP
    RNA; 2010 May; 16(5):1040-52. PubMed ID: 20348446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation is a regulatory mechanism in apolipoprotein B mRNA editing.
    Chen Z; Eggerman TL; Patterson AP
    Biochem J; 2001 Aug; 357(Pt 3):661-72. PubMed ID: 11463337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1.
    Yang Y; Sowden MP; Smith HC
    J Biol Chem; 2000 Jul; 275(30):22663-9. PubMed ID: 10833526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation, characterization and developmental regulation of the human apobec-1 complementation factor (ACF) gene.
    Henderson JO; Blanc V; Davidson NO
    Biochim Biophys Acta; 2001 Nov; 1522(1):22-30. PubMed ID: 11718896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reconstitution of mRNA editing in yeast using a Gal4-apoB-Gal80 fusion transcript as the selectable marker.
    Lellek H; Welker S; Diehl I; Kirsten R; Greeve J
    J Biol Chem; 2002 Jun; 277(26):23638-44. PubMed ID: 11976346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apobec-1 and apolipoprotein B mRNA editing.
    Chan L; Chang BH; Nakamuta M; Li WH; Smith LC
    Biochim Biophys Acta; 1997 Mar; 1345(1):11-26. PubMed ID: 9084497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of plasma LDL levels in normal and watanabe heritable hyperlipidemic rabbits.
    Greeve J; Jona VK; Chowdhury NR; Horwitz MS; Chowdhury JR
    J Lipid Res; 1996 Sep; 37(9):2001-17. PubMed ID: 8895066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased apoB100 mRNA in inbred strains of mice by estrogen is caused by decreased RNA editing protein mRNA.
    Srivastava RA
    Biochem Biophys Res Commun; 1995 Jul; 212(2):381-7. PubMed ID: 7626051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of a chaperone regulator, Bcl2-associated athanogene-4, in apolipoprotein B mRNA editing.
    Lau PP; Chan L
    J Biol Chem; 2003 Dec; 278(52):52988-96. PubMed ID: 14559896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression.
    Nakamuta M; Taniguchi S; Ishida BY; Kobayashi K; Chan L
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):747-55. PubMed ID: 9598833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-mediated protein transduction.
    Yang Y; Ballatori N; Smith HC
    Mol Pharmacol; 2002 Feb; 61(2):269-76. PubMed ID: 11809850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.